US 12,268,694 B2
Combination pharmaceutical agents as RSV inhibitors
Brian C. Shook, Holliston, MA (US); In Jong Kim, Lexington, MA (US); Thomas P. Blaisdell, Watertown, MA (US); Jianming Yu, Plainsboro, NJ (US); Joseph Panarese, Newton, MA (US); Kai Lin, Belmont, MA (US); Michael H. J. Rhodin, Stow, MA (US); Nicole V. McAllister, Groton, MA (US); and Yat Sun Or, Waltham, MA (US)
Assigned to Enanta Pharmaceuticals, Inc., Watertown, MA (US)
Filed by Enanta Pharmaceuticals, Inc., Watertown, MA (US)
Filed on Nov. 10, 2020, as Appl. No. 17/094,029.
Application 17/094,029 is a division of application No. 16/145,768, filed on Sep. 28, 2018, granted, now 10,881,666.
Claims priority of provisional application 62/566,159, filed on Sep. 29, 2017.
Claims priority of provisional application 62/566,160, filed on Sep. 29, 2017.
Prior Publication US 2022/0323460 A1, Oct. 13, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/5513 (2006.01); A61K 31/4439 (2006.01); A61K 31/7056 (2006.01); A61K 39/395 (2006.01); A61K 39/42 (2006.01); A61K 45/06 (2006.01); A61P 31/14 (2006.01); C07D 213/12 (2006.01); C07D 213/14 (2006.01); C07D 217/12 (2006.01); C07D 217/14 (2006.01); C07D 243/24 (2006.01); C07D 403/12 (2006.01); C07D 491/04 (2006.01); C07D 498/08 (2006.01); C07K 16/10 (2006.01)
CPC A61K 31/5513 (2013.01) [A61K 31/4439 (2013.01); A61K 31/7056 (2013.01); A61K 39/395 (2013.01); A61K 39/42 (2013.01); A61K 45/06 (2013.01); A61P 31/14 (2018.01); C07D 213/12 (2013.01); C07D 213/14 (2013.01); C07D 217/12 (2013.01); C07D 217/14 (2013.01); C07D 243/24 (2013.01); C07D 403/12 (2013.01); C07D 491/04 (2013.01); C07D 498/08 (2013.01); C07K 16/1027 (2013.01); C07K 2317/24 (2013.01); C07K 2317/76 (2013.01)] 4 Claims
 
1. A pharmaceutical composition comprising a compound which is

OG Complex Work Unit Chemistry
or a pharmaceutically acceptable salt thereof,
a second anti-respiratory syncytial virus agent; and
a pharmaceutically acceptable carrier or excipient.